C-13-X

C-13-X is an investigational chimeric antigen receptor T-cell (CAR-T) therapy being developed by Chongqing Precision Biotech for the treatment of solid tumors. The therapy is currently in early-stage development for indications including pancreatic cancer, lung cancer, and breast cancer. As a CAR-T cell therapy, it involves the genetic engineering of a patient's own T cells to express a chimeric antigen receptor that enables the immune system to recognize and eliminate malignant cells. While the specific molecular target for C-13-X has not been publicly disclosed on the developer's pipeline, it represents part of the company's expansion into solid tumor oncology.